source
- Novo Nordisk signs $2.6 billion deal with China's Hengrui for oral GLP-1/GIP candidateNovo Nordisk announced a licensing agreement with Chinese drugmaker Hengrui Pharmaceuticals, paying $300 million upfront for rights to a preclinical GLP-1/GIP dual-receptor agonist. The candidate,…
- Highlight Therapeutics reports positive Phase 2b results for BO-112 in high‑risk head and neck basal cell carcinomaHighlight Therapeutics announced that its Phase 2b study of BO-112 met the primary endpoint of visual and pathological response at week 24 in patients with localized high‑risk head and neck basal c…